Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Clinical Trials
162
Active:23
Completed:34
Trial Phases
5 Phases
Phase 1:64
Phase 2:29
Phase 3:40
+2 more phases
Drug Approvals
26
FDA:20
CANADA:2
PHILIPPINES:2
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (153 trials with phase data)• Click on a phase to view related trials
Phase 1
64 (41.8%)Phase 3
40 (26.1%)Phase 2
29 (19.0%)Not Applicable
18 (11.8%)Phase 4
2 (1.3%)Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
Not Applicable
Recruiting
- Conditions
- Hospital-acquired Bacterial Pneumonia (HABP)Ventilator-associated Bacterial Pneumonia (VABP)Complicated Intra-abdominal Infection (cIAI)Complicated Urinary Tract Infection (cUTI)Bloodstream Infection (BSI)
- Interventions
- Drug: Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT07089186
- Locations
- 🇨🇳
Huashan Hospital, Fudan Universit, Shanghai, China
To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.
Not Applicable
Recruiting
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Drug: QLM2010 for injection；dexamethasone
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 664
- Registration Number
- NCT07081256
- Locations
- 🇨🇳
Zhe jiangCancer Hospital, Hangzhou, China
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Not Applicable
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 602
- Registration Number
- NCT07079228
Pharmacokinetics and Pharmacodynamics Study
Not Applicable
Not yet recruiting
- Conditions
- Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C
- Interventions
- Drug: QLC7401 injectionDrug: RBD7022 injection
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT07074236
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University., Qingdao, China
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
Not Applicable
Recruiting
- Conditions
- Postmenopausal Women With Osteoporosis at High Risk of Fracture
- Interventions
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 278
- Registration Number
- NCT07062978
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital Bijie Hospital, Guizhou, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 28
- Next
News
No news found